Straits Times Index
3,204.57 +2.71 (+0.08%) S&P 500
4,574.79 +8.31 (+0.18%) Dow
35,756.88 +15.73 (+0.04%) Nasdaq
15,235.71 +9.01 (+0.06%) BTC-USD
62,096.51 -714.96 (-1.14%) CMC Crypto 200
1,500.74 -4.41 (-0.29%)
Novavax, Inc. (NVAX)
After hours: 04:16PM EDT
| Previous close | 135.35 |
| Open | 135.05 |
| Bid | 133.45 x 900 |
| Ask | 133.49 x 1000 |
| Day's range | 130.09 - 135.60 |
| 52-week range | 76.59 - 331.68 |
| Volume | 2,353,965 |
| Avg. volume | 5,377,050 |
| Market cap | 10.055B |
| Beta (5Y monthly) | 1.59 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -13.84 |
| Earnings date | 04 Nov 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 264.20 |
- Motley Fool
This Popular Stock Has a 93% Upside, According to Wall Street
If you had invested in Novavax (NASDAQ: NVAX) at the beginning of 2020, you'd be sitting pretty right now. Novavax's efforts to develop and market a vaccine for COVID-19 explain the company's terrific performance of late. The company's average price target of $264.20 implies gains of 93% from its share price of $136.86 as of this writing.
- Motley Fool
3 Top COVID Stocks -- Are They Tricks or Treats?
Taylor Carmichael (Novavax): Novavax's COVID-19 vaccine is still not on the market anywhere, which has made the stock a real wild ride for investors. The vaccine specialist started off 2020 so small it almost qualified as a micro-cap, with its stock priced at $4 a share. When COVID-19 hit, however, the stock took off.
- Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Novavax, Inc. (NVAX) on Behalf of Investors
LOS ANGELES, October 25, 2021--The Law Offices of Frank R. Cruz Announces Investigation of Novavax, Inc. (NVAX) on Behalf of Investors
